https://nova.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 Long-term disability trajectories in primary progressive MS patients: a latent class growth analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:36042 Wed 29 Jan 2020 16:35:27 AEDT ]]> Participant-centered online active surveillance for adverse events following vaccination in a large clinical trial: feasibility and usability study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:45032 P<.001). Conclusions: Vaxtracker is an effective tool for monitoring AEFIs in the 55 to 61 years age group. Participant response rates were high for both surveys, in both treatment arms and for each method of sending the survey. This study indicates that administration of 23vPPV was well-tolerated in this cohort. Vaxtracker has successfully demonstrated its application in the monitoring of adverse events in near-real time following vaccination in people participating in a national clinical trial.]]> Wed 26 Oct 2022 10:52:36 AEDT ]]> Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34855 Wed 24 May 2023 12:20:01 AEST ]]> Outcome measures in coeliac disease trials: The Tampere recommendations https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:47509 Wed 24 Jan 2024 15:29:08 AEDT ]]> Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33927 Wed 23 Jan 2019 15:30:44 AEDT ]]> Exacerbations of COPD https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55372 Wed 22 May 2024 15:00:48 AEST ]]> Current update on preclinical and clinical studies of resveratrol, a naturally occurring phenolic compound https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:37096 Wed 17 Nov 2021 16:30:40 AEDT ]]> A Global Core Outcome Measurement Set for Snakebite Clinical Trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50616 Wed 15 May 2024 14:22:36 AEST ]]> Country, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndrome https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:13693 Wed 11 Apr 2018 14:32:54 AEST ]]> Palliative medicine: my contribution to the development of an evidence base https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12236 Wed 11 Apr 2018 13:49:02 AEST ]]> The hospital outpatient alcohol project (HOAP): protocol for an individually randomized, parallel-group superiority trial of electronic alcohol screening and brief intervention versus screening alone for unhealthy alcohol use https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14418 Wed 11 Apr 2018 12:08:06 AEST ]]> How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55109 Wed 10 Apr 2024 08:53:58 AEST ]]> Oral isotretinoin for acne https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:35252 Wed 04 Dec 2019 11:35:50 AEDT ]]> How to include patient-reported outcome measures in clinical trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:39870 Tue 28 Jun 2022 14:26:14 AEST ]]> Virtual EPID standard phantom audit (VESPA) for remote IMRT and VMAT credentialing https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34305 Tue 26 Feb 2019 15:18:09 AEDT ]]> The benefits of data sharing and ensuring open sources of systematic review data https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51113 Tue 22 Aug 2023 13:58:56 AEST ]]> An Economic Model for Estimating Trial Costs with an Application to Placebo Surgery Trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:50324 Tue 18 Jul 2023 19:52:06 AEST ]]> Translational considerations for immunotherapy clinical trials in pediatric neuro-oncology https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52579 Tue 17 Oct 2023 15:49:01 AEDT ]]> Tackling Dementia Together via The Australian Dementia Network (ADNeT): A Summary of Initiatives, Progress and Plans https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:54222 Tue 13 Feb 2024 12:11:44 AEDT ]]> Who's really hypertensive?: quality control issues in the assessment of blood pressure for randomized trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:509 140/90 mmHg at the initial screening visit, 898 (24%) were not eligible for study entry after two further visits due to the elevated reading not being sustained. For both systolic and diastolic blood pressure recording, observed digit preference fell within 7 percentage points of the expected frequency. Protocol adherence, in terms of the required minimum blood pressure difference between the last two successive recordings, was 99.8%. These data suggest that adherence to blood pressure recording protocols and elimination of digit preferences can be achieved through appropriate training programs and quality control activities in large multi-centre community-based trials in general practice. Repeated blood pressure measurement prior to initial diagnosis and study entry is essential to appropriately characterize hypertension in these elderly patients.]]> Thu 25 Jul 2013 09:10:26 AEST ]]> Minimal disease activity for rheumatoid arthritis: a preliminary definition https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:604 Thu 25 Jul 2013 09:10:23 AEST ]]> The effect of lyophilised garlic on pharmacologically modifiable cardiovascular risk factors https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:22411 Thu 22 Sep 2016 10:55:42 AEST ]]> SEAFARER – A new concept for validating radiotherapy patient specific QA for clinical trials and clinical practice: SEAFARER - sensitivity of patient specific quality assurance, PSQA https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52206 5% increase in spinal cord dose relative to the original plans. Six plans (from four institutions) passed despite a >10% increase. Conclusions: This novel audit concept evolves beyond testing an institution’s ability to deliver a single test case, to increasing the number of errors caught by institutions themselves, thus increasing quality of radiation therapy and impacting every patient treated. Administered remotely this audit also provides advantages in cost, environmental impact, and logistics.]]> Thu 05 Oct 2023 10:15:47 AEDT ]]> T2-low: what do we know?: Past, present, and future of biologic therapies in noneosinophilic asthma https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52202 Thu 05 Oct 2023 10:09:05 AEDT ]]> Comprehensive Australasian multicentre dosimetric intercomparison: issues, logistics and recommendations https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:8352 Sat 24 Mar 2018 10:47:13 AEDT ]]> Progress in primary CNS lymphoma (commentary) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7930 Sat 24 Mar 2018 08:41:41 AEDT ]]> An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations standardising endpoints for clinical asthma trials and clinical practice https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7529 Sat 24 Mar 2018 08:38:29 AEDT ]]> Assuring high quality treatment delivery in clinical trials: results from the Trans-Tasman Radiation Oncology Group (TROG) study 03.04 "RADAR" set-up accuracy study https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:7330 Sat 24 Mar 2018 08:35:12 AEDT ]]> Dosimetric intercomparison for multicenter clinical trials using a patient-based anatomic pelvic phantom https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14366 Sat 24 Mar 2018 08:23:11 AEDT ]]> Clinical research is a priority for emergency medicine but how do we make it happen, and do it well? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:14868 Sat 24 Mar 2018 08:21:10 AEDT ]]> Challenges and lessons learned in conducting comparative-effectiveness trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:12773 Sat 24 Mar 2018 08:18:20 AEDT ]]> Effects of early intensive blood pressure-lowering treatment on the growth of hematoma and perihematomal edema in acute intracerebral hemorrhage: The Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10744 Sat 24 Mar 2018 08:08:21 AEDT ]]> Lower treatment blood pressure is associated with greatest reduction in hematoma growth after acute intracerebral hemorrhage https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:10748 Sat 24 Mar 2018 08:08:19 AEDT ]]> The role of olfactory challenge tests in incipient dementia and clinical trial design https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:18865 Sat 24 Mar 2018 08:03:15 AEDT ]]> Why inflammatory phenotyping is necessary for successful drug evaluation in asthma and COPD https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17293 Sat 24 Mar 2018 08:01:50 AEDT ]]> Recruitment rate for a clinical trial was associated with particular operational procedures and clinician characteristics https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:20056 Sat 24 Mar 2018 08:00:13 AEDT ]]> The evidence base for red blood cell transfusions https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:17221 Sat 24 Mar 2018 07:59:16 AEDT ]]> Design, manufacture, and evaluation of an anthropomorphic pelvic phantom purpose-built for radiotherapy dosimetric intercomparison https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:16972 Sat 24 Mar 2018 07:55:24 AEDT ]]> Health-related quality of life in chronic hepatitis B patients https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5136 Sat 24 Mar 2018 07:49:39 AEDT ]]> Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: Predictive value of centrally reviewed expression of estrogen and progesterone receptors - International Breast Cancer Study Group https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:5450 Sat 24 Mar 2018 07:48:10 AEDT ]]> Optimizing radiation therapy quality assurance in clinical trials: a TROG 08.03 RAVES substudy https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:26274 Sat 24 Mar 2018 07:40:16 AEDT ]]> Systematic review of universal school-based 'resilience' interventions targeting adolescent tobacco, alcohol or illicit substance use: a meta-analysis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31044 2 = 0.0, I² = 0%), but not tobacco or alcohol use. A similar result was found when studies assessed as high risk of bias were excluded. Overall intervention effects were evident for illicit substance use within multiple intervention characteristic subgroups, but not tobacco and alcohol. Such results support the implementation of universal school-based interventions that address ‘resilience’ protective factors to reduce adolescent illicit substance use, however suggest alternate approaches are required for tobacco and alcohol use.]]> Sat 24 Mar 2018 07:25:48 AEDT ]]> Improving informed consent: pilot of a decision aid for women invited to participate in a breast cancer prevention trial (IBIS-II DCIS) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:4802 Sat 24 Mar 2018 07:20:39 AEDT ]]> Evaluation of impact on health-related quality of life and cost effectiveness of traditional chinese medicine: a systematic review of randomized clinical trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23515 Sat 24 Mar 2018 07:17:17 AEDT ]]> A multicentre, randomized, double-blinded, placebo-controlled phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND) https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:23824 1·2, and absolute mismatch >10 ml) will be randomized to either tissue plasminogen activator or placebo. Study outcome: The primary outcome measure will be modified Rankin Scale 0–1 at day 90. Clinical secondary outcomes include categorical shift in modified Rankin Scale at 90 days, reduction in the National Institutes of Health Stroke Score by 8 or more points or reaching 0–1 at day 90, recurrent stroke, or death. Imaging secondary outcomes will include symptomatic intracranial haemorrhage, reperfusion and or recanalization at 24 h and infarct growth at day 90.]]> Sat 24 Mar 2018 07:12:50 AEDT ]]> Prioritizing clinical trial quality assurance for photons and protons: A failure modes and effects analysis (FMEA) comparison https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:52848 Mon 30 Oct 2023 09:53:46 AEDT ]]> EPID-based dosimetry for remote auditing of radiotherapy clinical trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34381 Mon 23 Sep 2019 11:51:41 AEST ]]> TMPRSS2 inhibitors for the treatment of COVID-19 in adults: a systematic review and meta-analysis of randomized clinical trials of nafamostat and camostat mesylate https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:55463 Mon 03 Jun 2024 10:08:13 AEST ]]> Disability accrual in primary and secondary progressive multiple sclerosis https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51685 Fri 15 Sep 2023 09:36:29 AEST ]]> Is it ethical to use teriflunomide as an active comparator in phase 3 trials? https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51536 Fri 08 Sep 2023 12:58:50 AEST ]]> Unlocking the DOOR-how to design, apply, analyse, and interpret desirability of outcome ranking endpoints in infectious diseases clinical trials https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51333 Fri 01 Sep 2023 10:11:17 AEST ]]>